<DOC>
	<DOCNO>NCT00635141</DOCNO>
	<brief_summary>This study examine effect hypertonic saline compare placebo Lung Clearance Index Cystic Fibrosis patient .</brief_summary>
	<brief_title>The Effect Hypertonic Saline Lung Clearance Index Patients With Cystic Fibrosis</brief_title>
	<detailed_description>The life expectancy patient Cystic Fibrosis ( CF ) greatly increased time due improve clinical care . While certainly beneficial CF patient , overall stability lung function make difficult assess effect therapeutic intervention . Currently , FEV1 ( forced expiratory volume 1 second ) remain primary outcome measure clinical trial , many CF patient normal pulmonary function annual rate decline le 2 % large specialized centre . Therefore , additional parameter need sensitive parameter define abnormality CF patient use therapeutic trial . One promising parameter Lung Clearance Index ( LCI ) . The LCI test quantify ventilation inhomogeneity assess washout inhale inert gas . Abnormalities gas clearance lung largely due retention inhaled gas due mucous obstruction lower airway . Interventions improve mucus accumulation expect improve LCI . Hypertonic saline show increase airway surface liquid ( ASL ) , mucociliary clearance pulmonary function . Therefore , study examine effect hypertonic saline compare placebo Lung Clearance Index Cystic Fibrosis patient .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Diagnosis CF define two clinical feature CF document sweat chloride &gt; 60 mEq/L quantitative pilocarpine iontophoresis test genotype show two well characterized disease cause mutation Informed consent verbal assent ( appropriate ) provide subject 's parent legal guardian subject 618 year age enrolment able perform reproducible spirometry Clinically stable enrolment FEV1 % predict â‰¥ 80 % calculate Wang reference equation Ability comply medication use , study visit study procedure Respiratory culture positive NTM B. cepacia complex within past year screening Use intravenous antibiotic oral quinolones within 14 day screen Investigational drug use within 30 day screen Physical finding screen would compromise safety participant quality study data</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Lung Clearance Index</keyword>
	<keyword>Hypertonic Saline</keyword>
	<keyword>Pediatrics</keyword>
</DOC>